Charles River Laboratories International, Inc. (NYSE:CRL) Shares Bought by Mizuho Securities USA LLC

Mizuho Securities USA LLC lifted its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 2,336.4% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 96,871 shares of the medical research company’s stock after purchasing an additional 92,895 shares during the quarter. Mizuho Securities USA LLC owned about 0.19% of Charles River Laboratories International worth $19,081,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Tortoise Investment Management LLC raised its stake in shares of Charles River Laboratories International by 77.0% during the 2nd quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock worth $27,000 after buying an additional 57 shares during the last quarter. Wolff Wiese Magana LLC purchased a new stake in Charles River Laboratories International in the 3rd quarter valued at approximately $32,000. Assetmark Inc. grew its holdings in Charles River Laboratories International by 1,153.3% during the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after buying an additional 173 shares during the last quarter. Headlands Technologies LLC acquired a new stake in Charles River Laboratories International during the 1st quarter valued at $41,000. Finally, Whittier Trust Co. of Nevada Inc. raised its holdings in shares of Charles River Laboratories International by 219.3% in the second quarter. Whittier Trust Co. of Nevada Inc. now owns 281 shares of the medical research company’s stock worth $58,000 after acquiring an additional 193 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on CRL shares. Baird R W cut Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 8th. Citigroup lowered shares of Charles River Laboratories International from a “neutral” rating to a “sell” rating and cut their price objective for the company from $215.00 to $175.00 in a research report on Tuesday, October 1st. UBS Group lifted their target price on shares of Charles River Laboratories International from $240.00 to $250.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. CLSA raised Charles River Laboratories International from an “underperform” rating to a “hold” rating and set a $205.00 price target on the stock in a research note on Thursday, November 7th. Finally, TD Cowen lifted their price objective on Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research report on Monday, November 11th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $217.54.

Insider Buying and Selling

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the transaction, the director now owns 12,386 shares in the company, valued at $2,676,862.32. This represents a 34.83 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Stock Performance

NYSE CRL opened at $187.74 on Friday. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14. Charles River Laboratories International, Inc. has a 1-year low of $176.48 and a 1-year high of $275.00. The firm has a market capitalization of $9.60 billion, a P/E ratio of 23.50, a P/E/G ratio of 5.33 and a beta of 1.38. The business’s 50-day simple moving average is $195.26 and its 200-day simple moving average is $207.52.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, beating analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $975.99 million. During the same period in the previous year, the company posted $2.72 earnings per share. Charles River Laboratories International’s revenue was down 1.6% compared to the same quarter last year. Equities analysts predict that Charles River Laboratories International, Inc. will post 10.19 EPS for the current year.

Charles River Laboratories International declared that its Board of Directors has authorized a stock repurchase plan on Wednesday, August 7th that permits the company to repurchase $1.00 billion in shares. This repurchase authorization permits the medical research company to repurchase up to 9.6% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its shares are undervalued.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).